title: Influence of mechanical stress on palmoplantar erythrodysesthesia--a case report.
abstract: BACKGROUND
  Cutaneous adverse events can have an important negative influence on quality of life and compliance in affected patients. Palmoplantar erythrodysesthesia (PPE; hand-foot syndrome) is a cutaneous toxicity associated with chemotherapeutic treatment, which necessitates treatment interruption or dose reduction in severe cases. This case report of pegylated liposomal doxorubicin-induced PPE shows the influence of mechanical stress on the development of skin lesions in various locations and the importance of patient education and compliance.
  
  
  METHODS
  We present the case of a 43-year-old female patient diagnosed with ovarian cancer and having undergone surgical and chemotherapeutic treatment. The development of extensive grade 3 PPE affecting numerous areas of the body particularly exposed to mechanical pressure necessitated dermatological treatment. The combination of local application of an antioxidant-containing ointment and the patient's compliance made it possible to continue chemotherapy without interruption or dose reduction.
  
  
  CONCLUSIONS
  The development of PPE often limits the use of chemotherapeutic agents, and this case report can provide a possible therapeutic and preventive strategy for affected patients.
authors.affiliation: Department of Dermatology, Venerology and Allergology, Center of Experimental and Applied Cutaneous Physiology, Charité - Universitätsmedizin Berlin, Germany.
authors.forename: Sora
authors.initials: S
authors.lastname: Jung
authors.forename: Jalid
authors.initials: J
authors.lastname: Sehouli
authors.forename: Alexa
authors.initials: A
authors.lastname: Patzelt
authors.forename: Jürgen
authors.initials: J
authors.lastname: Lademann
mesh_terms: D000328:Adult; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects; D000975:Antioxidants / Q000627:therapeutic use; D004317:Doxorubicin / Q000009:adverse effects*; D005260:Female; D060831:Hand-Foot Syndrome / Q000175:diagnosis / Q000209:etiology* / Q000517:prevention & control*; D006801:Humans; D010812:Physical Stimulation / Q000009:adverse effects*; D016896:Treatment Outcome
chemical_list: D000903:Antibiotics, Antineoplastic; D000975:Antioxidants; D004317:Doxorubicin